

**If you are completing Book 8 for BCPS
recertification, test sheets must be
postmarked by
January 17, 2006.**

This book is divided into three sections—Chronic Illnesses I, Chronic Illnesses II, and Chronic Illnesses III. You have the option of completing one, two, or all three modules. Please make certain to use a separate PSAP-V answer sheet for each and clearly mark which section you are doing.

Returning the answer sheet for BCPS recertification attests that you have completed the test as an individual effort and not in collaboration with any other individual or group. Failure to complete this test as an individual effort may jeopardize your ability to use PSAP for BCPS recertification.

Welcome from the Editorial Board

On behalf of the Editorial Board of the fifth edition of the *Pharmacotherapy Self-Assessment Program* (PSAP-V) and the American College of Clinical Pharmacy (ACCP), I would like to congratulate you on your purchase of this invaluable resource. Whether you are a returning subscriber, or a first-time buyer, and whether you purchased PSAP-V for recertification, for continuing education, or to help prepare for board certification, you will undoubtedly find the fifth edition of PSAP to be extremely pertinent to your understanding of pharmacotherapy.

ACCP strives to continuously improve its products. In this regard, PSAP-V has undergone many changes to make it even more useful to subscribers. Like previous editions, PSAP-V is composed of a series of books (11 in total) on topics ranging from cardiology to biostatistics. In this edition, the books have been divided into smaller, more manageable modules. Each book contains up to three modules, and each module contains between two and four chapters. These modules, and the accompanying assessments, can be completed independently—meaning that the subscriber does not necessarily have to read the entire book to get continuing education or recertification credit. The Editorial Board has recognized that being able to obtain credit from PSAP-V in these smaller, bite-sized chunks will benefit busy subscribers.

Another major change in PSAP-V is the use of footnotes to highlight for the reader key literature related to the materials in the text. These footnotes supplement rather than replace the annotated bibliography (which still is included, though it has been shortened).

Although PSAP has always been long recognized for its quality and timeliness, this has not come by happenstance. The PSAP-V Editorial Board has worked hard to ensure the continuing quality of this product. Expert authors have been

instructed to write their chapters by calling on their own vast experience in practice, and by conveying not only knowledge of the subject but also the passion that comes from years of dedication to a profession and to serving patients. The PSAP-V review process is extremely rigorous, much more so than traditional textbooks. Each chapter has been subjected to multiple reviews before being printed. In particular, special attention has been paid to the self-assessment questions and answers. This element of PSAP-V is one of the many things that differentiates it from other products and therefore is intensely scrutinized.

The PSAP-V Editorial Board recognizes that further improvements can always be made. We are constantly on the lookout for new and better ways of doing things. For this we can use your help. With each PSAP-V module a set of questions are included for you to provide feedback to the Editorial Board. We highly encourage you to complete these questions. We also encourage to give us your comments directly, via e-mail or phone. You can contact either me or Kristin Povilonis at ACCP. I guarantee that you will not only receive a response, but more importantly, that your input will be carefully considered by the entire Editorial Board.

PSAP is like no other product available in the field of pharmacotherapy. Though it is written in the style of a textbook, it is published quarterly, like a journal. PSAP-V provides the unique combination of highly advanced and contemporary content, a distinctive writing-style that emphasizes practical experience in the care of patients, and extensive continuing education/recertification credit. We hope that you find PSAP-V to be an indispensable part of your professional portfolio.

Glen T. Schumock, Pharm.D., M.B.A., FCCP, BCPS
Chair, PSAP Editorial Board

Acknowledgments

The general format of PSAP is modeled after the American College of Physicians' *Medical Knowledge Self-Assessment Program* (MK-SAP), currently in its 13th edition. ACCP gratefully acknowledges the advice and guidance provided by the American College of Physicians in the development of PSAP.

ACCP and the PSAP Editorial Board also wish to express our appreciation to the authors and reviewers. The success of this

unique pharmacotherapy self-assessment program is the direct result of the commitment by these outstanding clinical pharmacotherapy specialists.

Development and publication of the first edition of PSAP in 1991 was made possible by an educational grant from Sandoz Pharmaceuticals Corporation. ACCP will be forever grateful for its significant assistance in helping to launch this innovative program.

PHARMACOTHERAPY SELF-ASSESSMENT PROGRAM FIFTH EDITION

Editorial Board

Glen T. Schumock, Pharm.D., M.B.A., FCCP, BCPS (Chair)
Director and Associate Professor
Center for Pharmacoeconomic Research
University of Illinois at Chicago
Chicago, Illinois

Dianne M. Brundage, Pharm.D., FCCP, BCPS, BCOP
Clinical Pharmacy Specialist
Methodist Hospital/Park Nicollet Health Services
Minneapolis, Minnesota

Michelle M. (Chapman) Richardson, Pharm.D., FCCP, BCPS
Clinical Associate Professor
Northeastern University
Special and Scientific Staff

William B. Schwartz, M.D. Division of Nephrology
Tufts—New England Medical Center
Assistant Professor of Medicine
Tufts University School of Medicine
Boston, Massachusetts

Judy W.M. Cheng, Pharm.D., FCCP, BCPS
Associate Professor of Pharmacy Practice
Division of Pharmacy Practice
Long Island University
Brooklyn, New York
Clinical Pharmacy Specialist in Cardiology
Mount Sinai Hospital
New York, New York

Katherine Hammond Chessman, Pharm.D., FCCP,
BCPS, BCNSP
Associate Professor
Department of Pharmacy and Clinical Sciences
Pediatric Pharmacy Practice Residency Program Director
South Carolina College of Pharmacy
Medical University of South Carolina
Clinical Pharmacy Specialist
Pediatrics/Pediatrics Surgery
MUSC Children's Hospital
Charleston, South Carolina

Teresa S. Dunsworth, Pharm.D., FCCP, BCPS
Clinical Professor of Clinical Pharmacy
Department of Clinical Pharmacy
West Virginia University School of Pharmacy
Morgantown, West Virginia

Susan C. Fagan, Pharm.D., FCCP, BCPS
Professor of Pharmacy
Department of Clinical and Administrative Pharmacy
College of Pharmacy
University of Georgia
Adjunct Professor of Neurology
Medical College of Georgia
Augusta, Georgia

Adam B. Jackson, Pharm.D., BCPS
Clinical Pharmacy Specialist in Infectious Diseases
Department of Pharmacy
Kaiser Permanente—Colorado Region
Denver, Colorado

H. William Kelly, Pharm.D., FCCP, BCPS
Professor Emeritus, Pediatrics and Pharmacy
Department of Pediatrics, School of Medicine
University of New Mexico Health Sciences Center
Albuquerque, New Mexico

R. Chris Rathbun, Pharm.D., BCPS With Added
Qualifications in Infectious Diseases
Associate Professor
Clinical and Administrative Sciences, College of Pharmacy
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma

David J. Ritchie, Pharm.D., FCCP, BCPS
Clinical Pharmacist in Infectious Diseases
Barnes-Jewish Hospital
Professor of Pharmacy Practice
St. Louis College of Pharmacy
St. Louis, Missouri

Todd P. Semla, Pharm.D., M.S., FCCP, BCPS
Clinical Pharmacy Specialist
Benefits Management
U.S. Department of Veteran Affairs
Hines, Illinois
Associate Professor
Department of Psychiatry and Behavioral Sciences
The Feinberg School of Medicine
Northwestern University
Chicago, Illinois

Chronic Illnesses I Panel

Editorial Board Liaison

Teresa S. Dunsworth, Pharm.D., FCCP, BCPS
Clinical Professor of Clinical Pharmacy
Department of Clinical Pharmacy
West Virginia University School of Pharmacy
Morgantown, West Virginia

Barbara McCloskey, Pharm.D., BCPS, CDE
Diabetes Education Coordinator
Diabetes Services
Baylor Health Care System
Irving, Texas

Charles D. Ponte, Pharm.D., BCPS, BC-ADM, CDE
Professor of Clinical Pharmacy and Family Medicine
Schools of Pharmacy and Medicine
Robert C. Byrd Health Sciences Center
West Virginia University
Morgantown, West Virginia

Authors

Maureen E. Knell, Pharm.D., BCPS
Clinical Assistant Professor
Division of Pharmacy Practice
School of Pharmacy
University of Missouri—Kansas City
Saint Luke's Multi-Specialty Clinics
Kansas City, Missouri

Mary Lynn McPherson, Pharm.D., BCPS, CDE
Professor
Department of Pharmacy Practice and Science
University of Maryland School of Pharmacy
Baltimore, Maryland

Rheumatology: Osteoarthritis and Rheumatoid Arthritis

Eric J. MacLaughlin, Pharm.D., BCPS
Associate Professor and Division Head of Adult Medicine
Department of Pharmacy Practice
Texas Tech School of Pharmacy
Amarillo, Texas

Michelle M. (Chapman) Richardson, Pharm.D., FCCP, BCPS
Clinical Associate Professor
Northeastern University
Special and Scientific Staff
William B. Schwartz, M.D. Division of Nephrology
Tufts—New England Medical Center
Assistant Professor of Medicine
Tufts University School of Medicine
Boston, Massachusetts

Reviewers

The American College of Clinical Pharmacy and the authors would like to thank the following individuals for their careful review of the Book 8 chapters:

Nicola G. Dahl, Pharm.D.
Medical Writer
Kanab, Utah

David J. Ritchie, Pharm.D., FCCP, BCPS
Clinical Pharmacist in Infectious Diseases
Barnes-Jewish Hospital
Professor of Pharmacy Practice
St. Louis College of Pharmacy
St. Louis, Missouri

Chronic Pain Management: A Disease-based Approach

Peter J.S. Koo, Pharm.D.
Associate Clinical Professor of Pharmacy
Pharmacist Specialist, Pain Management
Department of Clinical Pharmacy and
Pharmaceutical Services
University of California at San Francisco
San Francisco, California

Chronic Illnesses II Panel

Editorial Board Liaison

Teresa S. Dunsworth, Pharm.D., FCCP, BCPS
Clinical Professor of Clinical Pharmacy
Department of Clinical Pharmacy
West Virginia University School of Pharmacy
Morgantown, West Virginia

Authors

Jacquelyn L. Bainbridge, Pharm.D., FCCP
Associate Professor
Department of Clinical Pharmacy and Department of Neurology
University of Colorado Health Sciences Center
Denver, Colorado

Melody Ryan, Pharm.D.
Associate Professor
Department of Pharmacy Practice and Science
University of Kentucky College of Pharmacy
Associate Professor
Department of Neurology
University of Kentucky College of Medicine
Clinical Pharmacy Specialist
Pharmacy Service
VA Medical Center
Lexington, Kentucky

Mary L. Wagner, M.S., Pharm.D.
Associate Professor
Ernest Mario School of Pharmacy
Department of Pharmacy Practice and Administration
Rutgers, The State University of New Jersey
Piscataway, New Jersey

Michael Z. Wincor, Pharm.D., BCPP
*Associate Professor of Clinical Pharmacy, Psychiatry, and
the Behavioral Sciences*
Associate Dean, External Programs
University of Southern California Schools of Pharmacy
and Medicine
Los Angeles, California

Reviewers

The American College of Clinical Pharmacy and the authors
would like to thank the following individuals for their
careful review of the Book 8 chapters:

Nicola G. Dahl, Pharm.D.
Medical Writer
Kanab, Utah

Julia Elenbaas, Pharm.D.
Belton, Missouri

Mary C. Gurnee, Pharm.D.
Pharmacist Consultant
Overland Park, Kansas

Seizure Disorders in Adults

Janine B. Fournier, Pharm.D., BCPS
Clinical Pharmacist
Pharmacy Clinical Operations
Kaiser Permanente
Martinez, California

James W. McAuley, Ph.D.
Associate Professor
Pharmacy Practice and Neurology
The Ohio State University Colleges of Pharmacy and
Medicine
Columbus, Ohio

Glen T. Schumock, Pharm.D., M.B.A., FCCP, BCPS
Director and Associate Professor
Center for Pharmacoeconomic Research
University of Illinois at Chicago
Chicago, Illinois

Headache

Dianne M. Brundage, Pharm.D., FCCP, BCPS, BCOP
Clinical Pharmacy Specialist
Methodist Hospital/Park Nicollet Health Services
Minneapolis, Minnesota

Susan R. Winkler, Pharm.D., BCPS
Assistant Director
Ambulatory Clinical Pharmacy Services
Clinical Associate Professor
Department of Pharmacy Practice
University of Illinois College of Pharmacy
Chicago, Illinois

Sleep Disorders

Melissa Blair, Pharm.D., BCPS, CDE
Wilmington, North Carolina

Teresa S. Dunsworth, Pharm.D., FCCP, BCPS
Clinical Professor of Clinical Pharmacy
Department of Clinical Pharmacy
West Virginia University School of Pharmacy
Morgantown, West Virginia

Cynthia K. Kirkwood, Pharm.D., BCPP
Associate Professor of Pharmacy
Vice Chair of Education
Virginia Commonwealth University
Richmond, Virginia

Chronic Illnesses III Panel

Editorial Board Liaison

Teresa S. Dunsworth, Pharm.D., FCCP, BCPS
Clinical Professor of Clinical Pharmacy
Department of Clinical Pharmacy
West Virginia University School of Pharmacy
Morgantown, West Virginia

Authors

Nina H. Cheigh, Pharm.D.
Clinical Associate Professor
Department of Pharmacy Practice
University of Illinois College of Pharmacy
Chicago, Illinois

Edith A. Nutescu, Pharm.D.
Clinical Associate Professor
Department of Pharmacy Practice
University of Illinois College of Pharmacy
Director
Antithrombosis Center
University of Illinois Medical Center
Chicago, Illinois

Philip T. Rodgers, Pharm.D., BCPS, CDE, CPP
Clinical Pharmacist
Duke University Health System
Clinical Assistant Professor
University of North Carolina at Chapel Hill
Director of Pharmacy Education
Duke Area Health Education Center
Durham, North Carolina

Karen A. Tisdell, Pharm.D., BCPS, CDE
Pharmacotherapy Specialist
Diabetes Health Center
McGuire VA Medical Center
Richmond, Virginia

Ann K. Wittkowsky, Pharm.D., CACP, FASHP
Clinical Professor
University of Washington School of Pharmacy
Director, Anticoagulation Services
University of Washington Medical Center
Seattle, Washington

Reviewers

The American College of Clinical Pharmacy and the authors would like to thank the following individuals for their careful review of the Book 8 chapters:

Nicola G. Dahl, Pharm.D.
Medical Writer
Kanab, Utah

Julia Elenbaas, Pharm.D.
Belton, Missouri

Mary C. Gurnee, Pharm.D.
Pharmacist Consultant
Overland Park, Kansas

Thrombosis: Treatment and Prevention in Patients With Chronic Illness

Todd P. Semla, Pharm.D., BCPS, FCCP
Clinical Pharmacy Specialist
Pharmacy Benefits Management and Strategic Health Group
Department of Veterans Affairs
Hines, Illinois
Associate Professor
Department of Psychiatry and Behavioral Sciences
The Feinberg School of Medicine
Northwestern University
Chicago, Illinois

Daniel M. Witt, Pharm.D., FCCP, BCPS, CACP
Manager
Clinical Pharmacy Services
Kaiser Permanente Colorado
Aurora, Colorado

Diabetes: Glycemic Control

Oralia Bazaldua, Pharm.D., BCPS
Associate Professor
Department of Family and Community Medicine
The University of Texas Health Science Center at San Antonio
San Antonio, Texas

Chronic Illnesses III Panel

Katherine Hammond Chessman, Pharm.D., FCCP,
BCPS, BCNSP

Associate Professor

Department of Pharmacy and Clinical Sciences
Pediatric Pharmacy Practice Residency Program Director

South Carolina College of Pharmacy

Medical University of South Carolina

Clinical Pharmacy Specialist

Pediatrics/Pediatrics Surgery

MUSC Children's Hospital

Charleston, South Carolina

Management of the Complications Associated With Diabetes

Susan C. Fagan, Pharm.D., FCCP, BCPS

Professor of Pharmacy

Department of Clinical and Administrative Pharmacy

College of Pharmacy

University of Georgia

Adjunct Professor of Neurology

Medical College of Georgia

Augusta, Georgia

Adam B. Jackson, Pharm.D., BCPS

Clinical Pharmacy Specialist in Infectious Diseases

Department of Pharmacy

Kaiser Permanente—Colorado Region

Denver, Colorado

Joseph J. Saseen, Pharm.D., FCCP, BCPS

Associate Professor

Departments of Clinical Pharmacy and Family Medicine

University of Colorado Health Sciences Center

Denver, Colorado

Dermatology

H. William Kelly, Pharm.D., FCCP, BCPS

Professor Emeritus, Pediatrics and Pharmacy

Department of Pediatrics, School of Medicine

University of New Mexico Health Sciences Center

Albuquerque, New Mexico

Kelly R. Ragucci, Pharm.D., BCPS, CDE

Associate Professor

Pharmacy and Clinical Sciences/Family Medicine

Medical University of South Carolina

Charleston, South Carolina

Disclosure of Potential Conflicts of Interest

Consultancies: Jacquelyn L. Bainbridge (Pfizer, Ortho McNeil); Dianne M. Brundage (Nabi, employer of spouse or significant other, Abbott, employer of spouse or significant other); Judy Cheng (sanofi-aventis, AstraZeneca, Kos Pharmaceuticals); Teresa S. Dunsworth (Medicaid P&T Board; West Virginia University Hospitals P&T Committee); Janine B. Fournier (Tarascon Pharmacoepia); H. William Kelly (National Institutes of Health, National Heart, Lung, and Blood Institute, Food and Drug Administration; Merck, AstraZeneca, Schering/Key); Peter J.S. Koo (Research Advisory Panel of California, Ortho McNeil); James W. McAuley (Epilepsy Foundation of America); Mary Lynn McPherson (Purdue Pharma, Endo); Edith A. Nutescu (AstraZeneca, Sanofi, Elsevier Science); Charles D. Ponte (National Certification Board for Diabetes Educators, Annals of Pharmacotherapy, APhA); Michelle M. Richardson (National Kidney Foundation, Agency for Health Care Research/Centers for Medicare and Medicaid Services, Amgen); Joseph J. Saseen (ASHP, Tarascon Pocket Pharmacoepia); Glen T. Schumock (Pfizer); Michael Z. Wincor (AstraZeneca); Susan R. Winkler (JCAHO); Ann K. Wittkowsky (The Medicines Company, AstraZeneca, GlaxoSmithKline, Novartis, Boehringer Ingelheim, sanofi-aventis).

Stock Ownership: Dianne M. Brundage (GlaxoSmithKline, equity owned by self and by spouse or significant other; Bristol Myers-Squibb, equity owned by self and by spouse or significant other); Glen T. Schumock (Sios, McKesson HBOC, Sepracor).

Royalties: Cynthia K. Kirkwood (American Pharmaceutical Association, Jobson Medical Information); Ann K. Wittkowsky (Facts and Comparisons Inc.).

Grants: Oralia Bazaldua (Pfizer); H. William Kelly (National Health, Lung, and Blood Institute, GlaxoSmithKline, AstraZeneca); Cynthia K. Kirkwood (GlaxoSmithKline); Eric MacLaughlin (Texas Tech Institute of Healthy Aging); James W. McAuley (Epilepsy Foundation of America); Mary Lynn McPherson (Novartis, Purdue Pharma); Edith A. Nutescu (AstraZeneca); Charles D. Ponte (Purdue Pharma LP); R. Chris Rathbun (Roche, Pharmacia, Bristol-Myers Squibb, Gilead Pharmaceuticals/Agouron Pharmaceuticals); Michelle M. Richardson (QualityMetric and Tufts-New England Medical Center); David J. Ritchie (Pfizer); Philip T. Rodgers (Bayer Diagnostics [now Ascensia], Novartis); Joseph J. Saseen (Forest Labs, Pfizer); Glen T. Schumock (Pfizer, AstraZeneca, National Institutes of Health, Mercy Resource Management, Inc., Pharmacia Corporation, Merck, Tap Pharmaceuticals, Dupont Pharmaceutical, Aventis, Searle); Susan R. Winkler (Illinois Department of Public Health); Ann K. Wittkowsky (Agency for Healthcare Policy and Research).

Honoraria: Jacquelyn L. Bainbridge (Pfizer, Ortho McNeil); Judy Cheng (Scios Inc); H. William Kelly (GlaxoSmithKline, AstraZeneca, Schering/Key, Novartis, Merck); Peter J.S. Koo (PharmMed/PriMed); Mary Lynn McPherson (Purdue Pharma); Edith A. Nutescu (GlaxoSmithKline, sanofi-aventis); Charles D. Ponte (Purdue Pharma); R. Chris Rathbun (GlaxoSmithKline, Agouron); Michelle M. Richardson (Amgen); David J. Ritchie (Pfizer); Philip T. Rodgers (Takeda, Kos Pharmaceuticals); Joseph Saseen (Merck, Forest Labs, Pfizer); Glen T. Schumock (ProCE, Inc.); Karen A. Tisdell (Kos Pharmaceuticals); Michael Z. Wincor (Sanofi-Synthelabo); Susan R. Winkler (Boehringer Ingelheim).

Other: R. Chris Rathbun (spouse or significant other performed contract research for Sanofi, Organon, Pharmacia, Aventis, Pfizer, AstraZeneca); Todd P. Semla (spouse or significant other employed by Abbott).

CONTINUING EDUCATION AND PROGRAM EVALUATION INSTRUCTIONS



Continuing Education Credit: The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. *Pharmacotherapy Self-Assessment Program* (PSAP) subscribers can earn 20.5 contact hours of continuing education credit for successfully completing the Chronic Illnesses Book of PSAP-V. The Universal Program Numbers are: Chronic Illnesses I 217-000-05-012-H01, 6.5 contact hours; Chronic Illnesses II 217-000-05-013-H01, 6.0 contact hours; and Chronic Illnesses III 217-000-05-014-H01, 8.0 contact hours.

To receive Continuing Pharmacy Education credit, a PSAP-V answer sheet must be returned for scoring. CE credit will be awarded for test scores 50% or greater. The answers to each CE test will be made available electronically to each participant after he or she has successfully completed the CE test. The answers will arrive with the participant's statement of credit. Those participants who desire to receive the answers in **printed** format must waive their opportunity to receive CE credit for any remaining unused CE programs that are included in this book, unless they submit the CE tests for those programs at the same time.

To receive the explained answers to the continuing education questions without submitting a CE test, fill out the top portion of the PSAP Test Answer Sheet for the applicable module and check the waiver statement, which states "Please send me the printed answers for the CE questions in the module indicated above. Because the answer book includes the answers to the other modules in this PSAP book, I waive my ability to submit future CE tests for those modules in this book that I have not submitted at this point." Answer books will be mailed with the Statements of Credit.

Book 8 Self-Assessment Questions

Directions: The self-assessment questions (items) can be found after each chapter. Each item consists of a question or incomplete statement followed by four lettered answers or completions. Please read each carefully and select the **one** lettered answer or completion that is **best** in each case. Completely blacken the corresponding lettered circle on the **test question** section of the enclosed PSAP-V answer sheet. Each book has two or more modules. **Use a separate answer sheet for each module. Only PSAP-V test sheets will be accepted.**

Book 8 Subscriber Evaluation

ACCP would like your assistance in evaluating the quality and usefulness of the Chronic Illnesses Book in PSAP-V. Answer sheets, provided with the book, include two sections: the first set of numbers (shaded) for the evaluation questions and next set of numbers for the test questions. Using a separate answer sheet for each module, please complete this evaluation in addition to the self-assessment questions. Indicate your response to the following questions by blackening the corresponding number in the **evaluation** area of the answer sheet that best represents your assessment.

1 = Definitely
agree

2 = Moderately
agree

3 = Cannot decide

4 = Moderately
disagree

5 = Strongly
disagree

Subscriber Evaluation – Chronic Illnesses I

1. The educational content of the material presented was appropriate for a pharmacotherapy specialist.
2. The level of difficulty of material presented was appropriate for a pharmacotherapy specialist.
3. I was satisfied with the content of the program.
4. I was satisfied with the administration of the program.
5. The program achieved its stated educational objectives.

Questions 6–11 apply to the chapter on Chronic Pain Management: A Disease-based Approach

6. The material presented was applicable to my practice.
7. The information presented was accurate and timely.
8. The material provided new information.
9. The material was clearly written.
10. The learning objectives were adequately assessed by the self-assessment questions.
11. The self-assessment questions were written clearly.

Questions 12–17 apply to the chapter on Rheumatology: Osteoarthritis and Rheumatoid Arthritis

12. The material presented was applicable to my practice.
13. The information presented was accurate and timely.
14. The material provided new information.
15. The material was clearly written.
16. The learning objectives were adequately assessed by the self-assessment questions.
17. The self-assessment questions were written clearly.

Subscriber Evaluation – Chronic Illnesses II

1. The educational content of the material presented was appropriate for a pharmacotherapy specialist.
2. The level of difficulty of material presented was appropriate for a pharmacotherapy specialist.
3. I was satisfied with the content of the program.
4. I was satisfied with the administration of the program.
5. The program achieved its stated educational objectives.

Questions 6–11 apply to the chapter on Seizure Disorders in Adults

6. The material presented was applicable to my practice.
7. The information presented was accurate and timely.
8. The material provided new information.
9. The material was clearly written.
10. The learning objectives were adequately assessed by the self-assessment questions.
11. The self-assessment questions were written clearly.

Questions 12–17 apply to the chapter on Headache

12. The material presented was applicable to my practice.
13. The information presented was accurate and timely.
14. The material provided new information.
15. The material was clearly written.
16. The learning objectives were adequately assessed by the self-assessment questions.
17. The self-assessment questions were written clearly.

Questions 18–23 apply to the chapter on Sleep Disorders

18. The material presented was applicable to my practice.
19. The information presented was accurate and timely.
20. The material provided new information.
21. The material was clearly written.
22. The learning objectives were adequately assessed by the self-assessment questions.
23. The self-assessment questions were written clearly.

Subscriber Evaluation – Chronic Illnesses III

1. The educational content of the material presented was appropriate for a pharmacotherapy specialist.
2. The level of difficulty of material presented was appropriate for a pharmacotherapy specialist.
3. I was satisfied with the content of the program.
4. I was satisfied with the administration of the program.
5. The program achieved its stated educational objectives.

Questions 6–11 apply to the chapter on Thrombosis: Treatment and Prevention in Patients with Chronic Illnesses

6. The material presented was applicable to my practice.
7. The information presented was accurate and timely.
8. The material provided new information.
9. The material was clearly written.
10. The learning objectives were adequately assessed by the self-assessment questions.
11. The self-assessment questions were written clearly.

Questions 12–17 apply to the chapter on Diabetes: Glycemic Control

12. The material presented was applicable to my practice.
13. The information presented was accurate and timely.
14. The material provided new information.
15. The material was clearly written.
16. The learning objectives were adequately assessed by the self-assessment questions.
17. The self-assessment questions were written clearly.

Questions 18–23 apply to the chapter on Management of the Complications Associated with Diabetes

18. The material presented was applicable to my practice.
19. The information presented was accurate and timely.
20. The material provided new information.
21. The material was clearly written.
22. The learning objectives were adequately assessed by the self-assessment questions.
23. The self-assessment questions were written clearly.

Questions 24–29 apply to the chapter on Dermatology

24. The material presented was applicable to my practice.
25. The information presented was accurate and timely.
26. The material provided new information.
27. The material was clearly written.
28. The learning objectives were adequately assessed by the self-assessment questions.
29. The self-assessment questions were written clearly.

For any Question you answered 4 or 5, please provide additional information in the Notes section of the answer sheet.

If you would like to provide additional comments, please provide them in the Notes section of the answer sheet.

Role of ACCP

ACCP developed the petition seeking recognition of Pharmacotherapy as a specialty of pharmacy and presented it to the Board of Pharmaceutical Specialties (BPS). As part of ACCP's mission to provide leadership, education, advocacy, and resources enabling clinical pharmacists to achieve excellence in practice and research, ACCP assists pharmacists in successfully sitting for the specialty certification examinations through publications such as *the Pharmacotherapy Self-Assessment Program (PSAP)*. ACCP also helps pharmacotherapy specialists maintain their certification through PSAP. ACCP reports successful completion of PSAP examinations to BPS for recertification credit. Neither ACCP nor its agents, including the PSAP Editorial Board, authors, reviewers, or other staff, have knowledge of specific examination content, areas of emphasis, or any other information that would compromise the integrity of the examination process.

Role of BPS

The Board of Pharmaceutical Specialties (BPS) is an administratively independent agency started by the American Pharmaceutical Association. BPS is totally separate and distinct from ACCP. The Board of Pharmaceutical Specialties, via its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects related to sitting for specialty certification examinations. PSAP has been approved by BPS for use in BCPS recertification. Questions regarding the number of hours required for BCPS recertification should be directed to:

Board of Pharmaceutical Specialties
2215 Constitution Ave., N.W.
Washington, DC 20037
(202) 429-7591
www.bpsweb.org

TABLE OF CONTENTS

Book 8

Preface	i
Editorial Board	ii
Book 8 Panel	iii
Disclosure of Potential Conflicts of Interest	vii
Continuing Education and Program Evaluation Instructions	viii
Roles of ACCP and BPS	xi

Chronic Illnesses I

CHRONIC PAIN MANAGEMENT: A DISEASE-BASED APPROACH	
Learning Objectives	1
Introduction	1
Pathophysiology of Pain	2
Nociceptive Pain	2
Transduction	2
Transmission	3
Perception	3
Modulation	4
Inflammatory Pain	4
Peripheral Sensitization	4
Phenotypic Switch	4
Central Sensitization	4
Neuropathic Pain	5
Ectopic Excitability	6
Structured Reorganization	6
Functional Pain	6
Analgesics	6
Nonopioid Analgesics	6
Acetaminophen	6

Nonsteroidal Anti-inflammatory Drugs	6
Tramadol	7
Opioids	7
Adjuvants	9
Antiepileptic Drugs	11
First-generation AEDs	11
Second-generation AEDs	11
Gabapentin	12
Other Second-generation AEDs	12
Antidepressant Drugs	12
Tricyclic Antidepressant	12
Selective Serotonin Reuptake Inhibitors	13
Serotonin-norepinephrine Reuptake Inhibitors and Other Antidepressant Drugs	13
Antiarrhythmic Drugs and Local Anesthetics	13
Topical and Other Adjuvant Analgesics	14
Capsaicin	14
Other Adjunctive Analgesics	14
Assessment of Pain	14
Pain Screening and Assessment	14
Knee Pain	15
Foot Pain	15
Pathogenesis of V.H.'s Pain	17
Treatment Plan for V.H.	17
Painful Diabetic Neuropathy	18
Pathophysiology	18
Assessment	18
Management	19
Post-herpetic Neuralgia	21
Pathophysiology	21
Assessment	21
Management	22
Low Back Pain	23
Pathophysiology	23
Assessment	24
Management	28
Acute LBP	28
Chronic LBP Management	29
Chronic Spinal Cord Injury Pain	31

Pathophysiology	31
Assessment	31
Management	33
The Role of the Pharmacist in Chronic Pain Management	35
Annotated Bibliography	35
Self-Assessment Questions	37

RHEUMATOLOGY: OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS

Learning Objectives	41
Introduction	41
Pathophysiology of Osteoarthritis	42
Definition and Epidemiology	42
Etiology and Pathophysiologic Findings	42
Classification and Risk Factors	43
Clinical Features	44
Diagnosis	44
Prognosis	44
Pathophysiology of Rheumatoid Arthritis	44
Definition and Epidemiology	44
Etiology and Pathophysiologic Findings	46
Clinical Features	47
Joint Involvement	47
Extra-articular Involvement	48
Diagnosis	48
Prognosis	48
Quality Patient Care	49
General Therapeutic Goals and Outcomes for Arthritis	49
Pharmacotherapy	49
Symptomatic Therapies for Osteoarthritis and Rheumatoid Arthritis: Topical Agents	49
Capsaicin	49
Other Topical Agents	50
Symptomatic Therapies for OA and RA: Systemic Analgesics/Anti-inflammatory Drugs	50
Acetaminophen	50
Nonsteroidal Anti-inflammatory Drugs and COX-2 Inhibitors	51
Efficacy of NSAIDs and COX-2 Inhibitors	52
Adverse Effects of NSAIDs and COX-2 Inhibitors	52
Gastrointestinal Complications	52
Therapeutic Strategies to Reduce the Risk of NSAID-Associated Complications	52
Cardiovascular Complications Associated with COX-2 inhibitors and NSAIDs	55
Other Adverse Effects of NSAIDs and COX-2 Inhibitors	57
Considerations for Using NSAIDs and COX-2 Inhibitors	58
Indication of Therapy	58
Selection of Drugs	58
Pharmacoeconomic Factors	59
Applying Clinical Judgment	59

Corticosteroids	59
Intra-articular Injections	59
Systemic Administration of Corticosteroids	61
Viscosupplementation	61
Dietary Supplements	62
Glucosamine and Chondroitin	62
Other Dietary Supplement Products	64
Opioids and Tramadol	64
Disease-modifying Drugs	64
Disease-modifying Osteoarthritic Drugs	65
Disease-modifying Antirheumatic Drugs	65
First-tier DMARDs	65
Hydroxychloroquine	65
Sulfasalazine	66
Methotrexate	66
Leflunomide	67
Tumor Necrosis Factor Antagonists	68
Interleukin-1 Receptor Antagonists	68
DMARDs for Special Situations	69
Tetracyclines	69
Combination DMARD therapy	69
Investigational Drugs for OA and RA	69
Nonpharmacological Therapy	70
Rest and Exercise	70
Nutrition, Weight Loss, and Dietary Therapy	70
Other Measures to Decrease Pain and/or Enhance Functional Ability	70
Treatment Plan	71
Algorithms and Guidelines	71
Osteoarthritis	71
Rheumatoid Arthritis	71
Treatments in Special Populations	71
Geriatric Patients	71
Women of Childbearing Age	72
Patients Taking DMARDs and Implications for Vaccinations	74
Treatment Outcomes and Monitoring	74
Monitoring Outcomes in OA	74
Monitoring Outcomes in RA	75
Monitoring of Drug Therapy in Arthritis	75
NSAIDs	75
DMARDs	75
Corticosteroids	76
Patient Education	76
Arthritis Self-management	76
Drug Therapy	76
Quality Improvement: The Pharmacist's Role	76
Efficiency	76
Efficacy and Effectiveness	76
Conclusion	79
Annotated Bibliography	79
Self-Assessment Questions	83

Chronic Illnesses II

SEIZURE DISORDERS IN ADULTS

Learning Objectives	91
Introduction	91
Pathophysiology	91
Definitions	91
Etiology	92
Clinical Characteristics	93
Diagnosis	93
History/Examination	93
Radiological Evaluation	93
Laboratory Evaluation	93
Electroencephalography	94
Epidemiology	94
Prognosis	94
Therapeutic Goals/Outcomes	95
Quality Patient Care	95
Pharmacotherapy	95
Therapy Initiation	95
Pharmacotherapy Refinements	96
Common Severe Adverse Effects/Interactions/ Therapeutic Contraindications	98
Nonpharmacological Therapy	98
Resection	98
Vagus Nerve Stimulation	100
Treatment Plan	100
Therapeutic End Points	100
Guidelines and Algorithm	101
Scottish Intercollegiate Guidelines Network	101
National Institute for Clinical Excellence	101
Prescribing RatiOnally using Decision support In General practice studY	102
Agency for Healthcare Research and Quality Evidence Report	102
American Academy of Neurology Practice Parameters	103
Effectiveness	103
Treatments of Choice in Special Populations	103
Women with Epilepsy	103
Decreased Fertility	103
Risk of Congenital Anomalies and Malformations	103
Management During Pregnancy	104
Postpartum Management	104
Contraception	104
Catamenial Epilepsy	104
Elderly	105
Physiological Changes	105
Comorbid Conditions	105
Adverse Effects	105
Discontinuation of an AED in Seizure-free Patients	105
Monitoring	106
Therapeutic Drug Monitoring	106
Bone Effects	106

Hypersensitivity	106
Adherence	107
System Support for Medication Use Process	107
Documentation That the Pharmacist Should Perform	107
Patient Education	107
Reducing the Patient's Perceived Burden of Illness	108
Assuring That the Patient's Goals of Therapy are Met	108
Special Directions and Precautions for Drug Preparation, Administration, and Use by the Patient	109
Drug Costs	109
Specific Issues Related to Drug or Disease-state Counseling in Different Patient Populations	109
Quality Improvement	110
Conclusion	110
Annotated Bibliography	110
Self-Assessment Questions	113

HEADACHE

Learning Objectives	117
Introduction	117
Tension-type Headache	118
Pathophysiology	118
Clinical Presentation	118
Diagnosis	118
Treatment Goals	118
Nonpharmacological Therapy	119
Pharmacological Therapy	119
Patient Education	119
Migraine Headache	119
Pathophysiology	119
Clinical Presentation	120
Migraine with Aura	120
Migraine Without Aura	121
Probable Migraine	121
Status Migrainosus	121
Diagnosis	121
Treatment Goals	121
Nonpharmacological Therapy	122
Pharmacological Therapy	122
Drug Management of the Acute Attack	122
Nonspecific Treatment	122
Specific Treatment	123
Ergotamines and Dihydroergotamines	123
Triptans	124
Selection of a Triptan	124
Dosing of the Triptans	125
Prevention	125
General Considerations when Starting a Preventive Drug	125
Antiepileptic Drugs	126
β -Blockers	126
Antidepressant Drugs	126

Calcium Channel Blockers	127	Acute Therapy	135
Other Drugs	127	Preventive Therapy	135
Patient-specific Treatment for Migraine	127	Other Therapy	135
Treatments Based on Clinical Situation	127	Patient Education	135
Patient Education	127	Medication Overuse Headache	135
Acute and Preventive Administration,		Conclusion	135
Precautions	127	Annotated Bibliography	135
Drug-drug Interactions	128	Self-Assessment Questions	137
Monitoring	128		
Cluster Headache	128		
Pathophysiology	128	SLEEP DISORDERS	
Clinical Presentation	129	Learning Objectives	141
Diagnosis	129	Introduction	141
Treatment Goals	129	Definition	141
Nonpharmacological Therapy	129	Sleep Stages and Sleep Architecture	141
Pharmacological Therapy	129	Function of Normal Sleep and Consequences of	
Acute	129	Abnormal Sleep	142
Preventive	130	Neurochemistry of Sleep	142
Short-term Preventives	130	Acetylcholine	143
Corticosteroids	130	Norepinephrine	143
Methysergide	130	Histamine	143
Ergotamine	130	Serotonin	143
Long-term Preventives	130	Dopamine	143
Verapamil	130	Orexin	143
Lithium Carbonate	130	Adenosine	143
Antiepileptic Drugs	130	Gamma-aminobutyric Acid	144
Melatonin	130	Classification of Sleep Disorders	144
Patient-specific Treatment	130	Diagnosing, Assessing, and Monitoring of Sleep	
Patient Education	131	Disorders	145
Other Trigeminal Autonomic Cephalgias	131	Subjective Tests	145
Pathophysiology	131	Objective Tests	146
Paroxysmal Hemicrania	131	Therapeutic Goals and End Points	147
Short-lasting Unilateral Neuralgiform Headache		Insomnia	147
Attacks with Conjunctival Injection and Tearing	131	Definition and Consequences of Poor Sleep	147
Cervicogenic Headache	131	Economic Impact	147
Temporomandibular Joint Dysfunction	131	Epidemiology	147
Clinical Presentation	131	Classification and Assessment of Insomnia	147
Diagnosis	131	Treatment	148
Treatment Goals	132	Nonpharmacological Treatment	148
Pharmacological Therapy	132	Sleep Hygiene Education	148
Patient Education	132	Relaxation Therapy	148
Other Primary Headaches	132	Stimulus Control	148
Pathophysiology	132	Sleep Restriction	148
Clinical Presentation	132	Cognitive Restructuring	149
Diagnosis	132	Bright Light Therapy	149
Chronic Transformed Migraine	132	Pharmacological Treatment	149
Chronic-tension Type Headache	132	Benzodiazepine Receptor Agonists	149
New Daily Persistent Headache	132	Memory Impairment and Anterograde	
Treatment Goals	133	Amnesia	150
Pharmacological and Nonpharmacological		Tolerance	151
Therapy	133	Withdrawal and Rebound	151
Chronic Daily Headache with Drug Overuse		Physiological Dependence	151
in the Outpatient Setting	133	Respiratory Depression	152
Chronic Daily Headache with Drug Overuse		Cautions	152
and Admitted for Inpatient Detoxification	133	Drug Interactions	152
Behavior Treatment	135		

Taper Plan	152
Drugs Recently Approved, Awaiting Approval, or Under Investigation	153
Eszopiclone	153
Ramelteon	153
Other	153
Antidepressant Drugs	153
Antihistamine Drugs	154
Antipsychotic Drugs	154
Herbal and Supplement Therapies	155
Melatonin	155
Valerian	156
Treatment Guidelines	156
Patient Education	157
Quality Improvement	157
Hypersomnolent Sleep Disorders	158
Sleep Apnea	158
Obstructive Sleep Apnea	158
Central Sleep Apnea	159
Narcolepsy	159
Description	159
Treatment	159
Sleep-related Movement Disorders	160
Restless Legs Syndrome	160
Description and Epidemiology	160
Treatment	160
Periodic Limb Movements of Sleep	161
Conclusion	161
Annotated Bibliography	161
Self-Assessment Questions	163

Chronic Illnesses III

THROMBOSIS: TREATMENT AND PREVENTION IN PATIENTS WITH CHRONIC ILLNESSES	
Learning Objectives	169
Introduction	169
Preventing Venous Thromboembolism in Hospitalized Medically Ill Patients	169
Preventing VTE in Orthopedic Surgery	171
Pharmacological Options and Comparative Outcomes	172
Total Hip Replacement Surgery	172
Total Knee Replacement Surgery	173
Hip Fracture Surgery	174
Timing of Prophylaxis Initiation	174
Prophylactic Therapy Duration	175
Preventing and Treating VTE in Patients with Hypercoagulable Conditions	175
Therapy Duration in Patients with Hypercoagulable Conditions	176
Primary Prophylaxis in Asymptomatic Carriers	176
Oral Contraceptive Use in Patients with Thrombophilia	177
Preventing and Treating VTE in Patients with a Malignancy	177

VTE Prevention in Malignancy	177
VTE Treatment in Malignancy	178
Anticoagulant Use in Special Populations	179
Monitoring Considerations	180
Obesity	180
Renal Impairment	181
Managing Anticoagulation in Patients Undergoing Invasive Procedures	182
Evaluating Thrombosis Risk	182
Evaluating Bleeding Risk	183
Clinical and Practical Considerations in Designing a Bridge Therapy Plan	184
Conclusion	185
Annotated Bibliography	185
Self-Assessment Questions	187

DIABETES: GLYCEMIC CONTROL

Learning Objectives	193
Introduction	193
Epidemiology	193
Nomenclature	194
Pathophysiology	194
Type 2 Diabetes Mellitus	194
Type 1 Diabetes Mellitus	195
Gestational Diabetes Mellitus and Other Forms	195
Screening	195
Prevention of Diabetes Mellitus	196
Diagnosis	197
Treatment Goals	198
Quality Patient Care	198
Lifestyle Management	198
Diet Management: An Evidence-based Approach	198
Exercise and Activity	198
Stress and Depression Management	199
Pharmacotherapy	199
Nonsulfonylurea Secretagogues	199
Thiazolidinediones	200
Mechanism of Action	200
Clinical Application	200
Adverse Events and Other Clinical Effects	201
New Rapid-acting Insulins	201
Clinical Application	202
New Long-acting Insulins	202
Clinical Application	202
Emerging Therapies	203
Inhaled Insulin	203
Glucagon-like Peptide-1 Agonists	204
DPP-IV Inhibitors	204
Pramlintide	204
Dual PPAR Agonists	204
Treatment Plan	205
Monitoring	206
Traditional Blood Glucose Monitors	206
Nontraditional Monitors	206
Patient Education	207
Low Literacy Issues	207

Self-management Education	207
Quality Improvement	208
The Healthy People 2010 Report on Diabetes	208
Research End Points and Quality of Life Indicators	208
Summary	209
Annotated Bibliography	210
Self-Assessment Questions	213

**MANAGEMENT OF THE COMPLICATIONS
ASSOCIATED WITH DIABETES**

Learning Objectives	219
Introduction	219
Pathophysiology of Chronic Complications	219
Microvascular Complications	220
Oxidative Stress	220
Advanced Glycation End Products	220
Aldose Reductase (Polyol) Pathway	220
Hexosamine Pathway	221
Protein Kinase C	221
Hormones, Cytokines, Growth Factors, and Vasomotor Mediators	221
Inflammation	221
Macrovascular Complications	221
Abnormal Lipoproteins	222
Prothrombosis	222
Overall Risk of Developing Chronic Complications	222
Microvascular Complications	223
Macrovascular Complications	223
General Management for the Prevention of Complications	223
Glycemic Control	223
Postprandial Hyperglycemia	225
Blood Pressure Control	225
Lipid Control	226
Multifactorial Approach	226
Patient Education	227
Chronic Complications	227
Microvascular	227
Retinopathy	227
Stages of Retinopathy	227
Assessment	228
Management	228
Glycemic Control	228
Blood Pressure Control	228
Other Interventions	229
Surgery	229
Nephropathy	229
Assessment	230
Microalbuminuria	230
Macroalbuminuria	230
Chronic Kidney Failure	230
Management	230
Blood Pressure Control	230
ACE Inhibitors Versus ARBs	231
Protein Restriction	231
Neuropathy	232

Autonomic	232
Cardiovascular	233
Gastrointestinal	233
Genitourinary	233
Other	234
Sensorimotor (Peripheral)	234
Assessment	234
Management of Painful Neuropathy	236
Foot Ulcers	236
Prevention and Management	236
Macrovascular Complications	237
Management	238
Dyslipidemia	238
Hypertension	239
Aspirin	240
Other Preventive Modalities	240
Special Populations	240
Latent Autoimmune Diabetes in Adults	240
Pregnancy	240
Elderly	241
Children	241
Patient Quality Improvement	241
Conclusion	242
Annotated Bibliography	242
Self-Assessment Questions	245

DERMATOLOGY

Learning Objectives	251
Introduction	251
Acne Vulgaris	251
Pathophysiology	251
Classification	252
Topical Acne Therapy	252
Benzoyl Peroxide	252
Azelaic Acid	252
Salicylic Acid and Sulfur	253
Retinoids	253
Antibacterial Agents	253
Systemic Acne Therapy	253
Oral Antibiotic Drugs	254
Oral Isotretinoin	254
Systemic Hormonal Therapy	255
Patient Education/Counseling	255
Psoriasis	256
Pathophysiology	256
Topical Therapy	256
Emollients and Keratolytics	256
Anthralin	256
Coal Tar	257
Corticosteroids	257
Calcipotriene	257
Tazarotene	257
Systemic Therapy	258
Methotrexate	258
Cyclosporine	258
Acitretin	259

Phototherapy	259
Biologic Therapy	259
Etanercept	259
Infliximab	260
Efalizumab	260
Alefcept	260
Combination Strategies	260
Atopic Dermatitis	260
Topical Therapy	261
Corticosteroids	261
Tar Preparations	262
Immunomodulators	262
Ultraviolet Light	262
Systemic Therapy	262
Immunosuppressants	262
Corticosteroids	262
Cyclosporine	263
Azathioprine	263
Antimetabolites	263
Other Therapies	263
Antihistamines	263
Wet Dressings/Occlusion	263
Treatment	263
Conclusion	264
Annotated Bibliography	264
Self-Assessment Questions	267